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Abstract
Background: Epidemiologic studies have shown conflicting results regarding the role of traffic pollution in the
development of allergic disease. This study investigated the relationship between living close to traffic and ever
dispense of prescribed oral antihistamines or nasal anti-allergic medication, among young children. The underlying
aim was to investigate if children growing up close to traffic pollution are at higher risk of developing allergy in
early childhood.
Methods: We investigated a birth cohort in southern Sweden, consisting of N = 26 128 children (0–6 years) with
health outcome and exposure data. Of these children, N = 7898, had additional covariate information. Traffic
intensity and yearly averages of dispersion-modeled concentrations of NOX (100 × 100 m grid) at residential
addresses, were linked with registry data on dispensed allergy medication (the Swedish Prescribed Drug Register).
Individual level covariate information was obtained from questionnaires distributed to parents at Child Health
Care-center visits, eight months after birth. Cox proportional hazards regression was used for the statistical analyses.
Results: Living in close proximity to a road with equal to or greater than 8640 cars/day (compared to 0–8639
cars/day), was not associated with higher incidence of ever dispensed oral antihistamine or nasal anti-allergic
medication, with or without adjustment for confounders (sex, breastfeeding, parental allergy, parental origin,
season, and year of birth). Similar results were found in relation to NOX.
Conclusions: Traffic-related exposure was not associated with higher incidence of ever dispensed medication
against allergy, in children 0–6 years in southern Sweden. These results indicates that traffic-related exposure may
not be a risk factor for early onset allergy in children in southern Sweden. However, children with dispense of
prescribed allergy medication may be a selected subgroup, and the results for this group may not be generalizable
to all children with allergy.
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Background
Experimental studies suggests that air pollution from
traffic can cause or enhance allergic symptoms [1], but
epidemiological studies are more inconsistent [2–4].
In childhood, allergic disease often develops in a pre-
dictable way in individuals with an allergic predispos-
ition, “the allergic march”. This starts with eczema and
food allergy in early childhood, followed by a higher risk
of wheeze and infectious asthma in pre-school age, and
allergic asthma and allergic rhinitis in subsequent age
[5]. Allergic rhinitis is uncommon in early childhood,
but the prevalence increases in preschool and school age
[6]. The natural history of asthma and its relation to
traffic has been discussed in a previous article [7].
The main drug used for allergic symptoms are oral anti-
histamines, which have systemic anti-allergic effect, and
are prescribed for food allergy symptoms, such as urti-
caria, and for allergic rhinitis. An alternative or comple-
mentary treatment for allergic rhinitis is locally inhaled
nasal corticosteroids/other nasal anti-allergics which are
used mainly for allergic rhinitis. Oral antihistamines and
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nasal corticosteroids are often prescribed by doctors, but
can also be bought over the counter, without a prescrip-
tion. However, a doctor prescription is more likely to be
specific for allergic symptoms, since clinical examination/
anamnesis excludes infectious rhinitis as a cause. Some
studies have used purchase of inhaled oral antihistamines/
nasal corticosteroids as a proxy for seasonal allergic rhin-
itis incidence or prevalence [8].
The Swedish Prescribed Drug Register has a complete
(99.7 %) coverage of individual-level dispensed medica-
tion for all individuals living in Sweden [9], and dis-
pensed allergy medication will in this study be used as a
proxy variable for incidence of allergy. Dispersion-
modelled levels of outdoor Nitrogen Oxides (NOX) and
data on traffic intensity residential addresses were used
to estimate children’s exposure to traffic pollution. The
underlying aim was to investigate if children growing up
close to traffic pollution are at higher risk of developing
allergy in early childhood.
Methods
Study area
Scania is the southernmost county of Sweden, with a
population of 1 243 329, in year 2010 [10]. Children
born in Scania, whose mothers were registered as living
in one of the municipalities Malmö, Svedala, Vellinge
and Trelleborg were included, since survey data with co-
variate information were available from Child Health Care
centers (CHC) in these areas.
Malmö has the highest level of air pollution in the
area. Although pollutant levels in the region are low in a
European context, they are higher than in most of
Sweden, due to long-range transport of pollutants from
the continent and extensive transport/road, harbor and
ferry traffic. The study area has been described in detail
previously [11, 12].
Selection of study population
A flow-chart of the study population selection is displayed
in Fig. 1. The study was limited in time to children born
from July 2005, since individual level medication data is
only available since then. All children were followed with
health outcome data to the end of 2011.
To identify a birth cohort, we retrospectively retrieved
the identity number of all children born by mothers liv-
ing in Malmö, Svedala, Vellinge and Trelleborg during
July 2005- Dec 2010, from the Perinatal Revision South
(PNS)-registry. The PNS registry has 100 % coverage of
visits on obstetric and peri/prenatal units in the county.
Out of 28 037 children identified in the PNS-register,
875 were not found in the Scania population registry
and thus excluded, since they were not registered as living
in the region during childhood. Health outcome data was
available for all children found in the Scania population
registry (n = 27 162), by linkage to the Swedish Prescribed
Drug Register. Geographical coordinates (geocodes) for
registered birth year address was available for 26 128 chil-
dren, for which exposure was assessed. Most of the miss-
ing geocodes belonged to children born in December,
whose late birth date probably lead to addresses not being
registered during year of birth. Geocodes were retrieved
for birth year and subsequent years for each child, until
the end of 2010. Finally, covariate information from
questionnaires routinely distributed at Child Health Care
centers was available for 7898 children, which formed the
main study cohort.
Ethical permission
This study was approved by the Lund University Ethical
Committee (registration no. 2011/468). No formal in-
formed consent was required, but the study was advertised
in the local newspaper and information was distributed to
Child Health Care centers, allowing parents to request
that their children not be included in it. No such request
was raised.
Allergy medication
The Swedish Prescribed Drug Register includes all drugs
dispensed at pharmacies in Sweden, since July 2005
linked to personal identity numbers [13]. The registry is
maintained by the National Board of Health and Welfare.
All expedited drugs on the pharmacies are registered, with
a very small number of incorrect or incomplete registra-
tions of ID. The population coverage with correct patient
identities is 99.7 % [9].
The registry contains data on all dispensed prescrip-
tions in ambulatory care. Over-the-counter (OTC) medi-
cations and drugs used at in-patients settings are not
included. Medication data are classified according to the
Anatomical Therapeutic Chemical (ATC) Classification
System [14].
The Pharmaceutical Benefit Scheme, which is mainly
tax financed, covers the main costs for drugs in ambula-
tory care in Sweden. There is a ceiling on the total amount
that a patient pays during a 12-month period for subsi-
dized pharmaceuticals (2013: SEK 2200, €252). The drug
costs of children younger than 18 years, living in the same
household, are counted together.
We obtained information on medications prescribed
for allergy. The health outcomes used were dispensed
prescription of oral antihistamines (ATC-codes: R06),
nasal corticosteroids (ATC-codes: R01AD), and nasal anti-
allergic agents excl. corticosteroids (R01AC).
As primary health outcomes we used:
1) Incidence of first ever dispensed oral antihistamine
2) Incidence of first ever dispensed nasal
corticosteroid/other nasal anti-allergics
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First dispensed oral antihistamine was seen as a proxy
for incidence of allergy, but is non-specific. First dis-
pensed nasal corticosteroid/nasal anti-allergics was seen
as a proxy for incidence of allergic rhinitis.
Exposure assessment
Geocodes for the children’s officially registered residen-
tial addresses were retrieved from the population registry
for each year from birth until the end of 2010. Although
health outcome data are available until end of 2011, the
exposure data are thus only available until end of 2010.
Individuals are geographically positioned at the center
coordinate of their residence.
Traffic intensity
A Geographical Information System (GIS) based registry
from the Swedish National Road Database, provided data
on traffic intensity in all major roads in the county. To
assess exposure to traffic, we identified the road with the
heaviest traffic intensity within 100 m of the residence.
Traffic intensity was categorized as “no road”, “road
with 0–2879 cars/day”, “2880–8639 cars/day”, “8640–
14,400 cars/day”, and “≥14,400 cars/day”, based upon daily
(24-hour) mean levels.
The traffic intensity categories were merged into a
dichotomous variable, “0–8639 cars/day” (including chil-
dren with “no road”) and “≥8640 cars/day”, to obtain
enough power, since not enough cases lived in the high-
est exposure category to assess it separately. The classifi-
cation was based upon results from previous studies in
the same geographical region, which found a higher
prevalence of asthma among adults living within 100 m
of roads with ≥8640 cars/day [15, 16]. Separate analyses
were done in relation to traffic intensity for: 1) birth ad-
dress exposure 2) birth address exposure, with children
censored when/if they moved during time at risk.
Fig. 1 Selection of study population
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Modeled concentrations of NOX
Concentrations of NOX (NO2 + NO) at each child’s
residential address were modeled as annual means for
each calendar year 2005–2010, with a spatial reso-
lution of 100 × 100 m. This has previously been de-
scribed in detail [12]. Validation of this model with a
resolution of 100 × 100 m has shown satisfying agree-
ment between modeled and measured concentrations
of NO2 (Spearman’s r = 0.8) [17].
Separate NOX -analyses were done for: 1) birth address
exposure 2) birth address exposure, with children cen-
sored when/if they moved during time at risk, and 3)
mean NOX during all years at risk (excluding 2011 for
which geocodes were not available). The mean NOX dur-
ing time at risk was only assessed for those never mov-
ing outside the study area during time at risk. Since time
at risk differ with health outcome, the number with
modeled mean NOX during time at risk, also vary de-
pending on health outcome.
We used a categorical classification of NOX, since pre-
vious studies in the same geographical region have indi-
cated non-linear relationship between outdoor NOX and
respiratory disease [15, 16]. We based our categories on
exposure contrasts (≤15, 15–25 and >25 μg/m3), rather
than on the distribution of NOX in the population.
Covariate information
The final cohort for the main analysis included 7898
children born in the region, whose parents had answered
a CHC center questionnaire 8 months after birth. The
questionnaire was handed out to parents in Malmö,
Svedala, Vellinge and Trelleborg, in conjunction with
their children’s 8 month checkup at the CHC centers
[18]. The questionnaire had been validated and translated
from Swedish into five different languages: Albanian,
Arabic, English, Serbo-Croatian, and Somali. The response
rate varied between years but was approximately 65 % of
handed out questionnaires [18].
Variables considered for inclusion in the multivariable
models were: sex, birth weight, smoking during pregnancy,
environmental tobacco smoke (ETS), mold at home, par-
ental allergy, furred pets at home, breastfeeding, parental
origin, parental education, problems to pay bills, type of
housing, season, and birth year.
Statistics
All statistical analyses were performed using SAS, ver-
sion 9.3. Survival analysis was performed because of dif-
ferent lengths of follow-up of the children. We used the
same analysis plan as in a previous article on childhood
respiratory disease [7].
We used two different censoring variables: 1) children
were censored at year of study end (2011), or 2) children
were censored when they moved from their original
birth address, or at year of study end (2011). Descriptive
Kaplan-Meier survival curves, with numbers at risk,
were displayed for all health outcomes. The proportional
hazard assumptions for exposure and health outcome
were checked graphically by log(−log(survival))-curves,
and these were approximately fulfilled for the larger
cohort (n = 26 128), but not for all health outcomes in
the smaller main sample (n = 7898) which was expected
since the smaller cohort is less numerically stable.
We then reported unadjusted Cox Proportional Hazards-
ratios (Cox PH) between exposure and health outcomes.
We used prescreening of variables in combination with a
stepwise Cox PH-procedure, to select covariates to include
in the final multivariable models. We performed the same
selection procedure for all health outcomes in relation to
traffic intensity, to find the most important predictors. Any
variable staying in any of the health outcome models, was
included in all the models, for model consistency. Traffic
intensity was forced to remain in the model in each step.
The following steps were done:
1. Univariable prescreening of all covariates in Table 1,
except municipality. Any variable with a univariate
p-value <0.2 for the hazard ratios (HR) between the
covariate and the health outcome, was selected to
next step.
2. All the selected variables were included into a
multivariable Cox PH model, together with traffic
intensity which was forced to stay in the model.
Backward selection was performed, with significance
level for staying at 0.1.
3. Starting with an initial model including the variables
selected from step 2. Forward selection was
performed, with significance level for entry at 0.2, to
consider for inclusion the variables initially not
selected at step 1.
4. Starting with the model selected from step 3.
Finetuning was done by stepwise selection- entry/
staying at 0.05. The variables selected to be included
in the final multivariable models were: Sex,
breastfeeding, parental allergy, parental origin,
season, and year of birth.
All selected covariates except year of birth approxi-
mately fulfilled the proportional hazard-assumption, and
we used the Cox PH model for the final multivariable
analyses, to assess the incidence of asthma medication
and diagnoses in relation to traffic-related exposures.
Multivariable analyses presented do not include children
with missing values for any of the variables included.
We also performed sensitivity analyses: we analyzed
the unadjusted relation between traffic-related exposure
and health outcomes, for all children with complete in-
formation on exposure and health outcome (n = 26 128).
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Table 1 Description of the main cohort, n = 7898
N (%) HR (95 % CI)a
Nasal anti-allergics Oral antihistamine
1st purchase 1st purchase
Sex Girl 3784 (49) 1.0 1.0
Boy 3996 (51) 1.40 (1.04–1.90) 1.03 (0.95–1.12)
Missing 118
Birth weight 2500–4000 (normal) 6079 (78) 1.0 1.0
500–2499 (low) 301 (4) 1.38 (0.70–2.71) 0.98 (0.78–1.22)




No 7275 (94) 1.0 1.0




No 6591 (85) 1.0 1.0
Yes 1177 (15) 0.89 (0.58–1.36) 0.97 (0.86–1.09)
Missing 130
Breastfeeding ≥8 months 3920 (56) 1.0 1.0
<8 months 2807 (40) 0.91 (0.67–1.24) 1.19 (1.09–1.30)
Never breastfed 278 (4) 0.79 (0.32–1.95) 1.08 (0.86–1.36)
Missing 893
Parental allergy No 3177 (46) 1.0 1.0
Yes 3751 (54) 1.18 (0.86–1.62) 1.14 (1.05–1.25)
Missing 970
Furred pets at home No 5790 (75) 1.0 1.0
Yes 1922 (25) 1.12 (0.80–1.56) 1.13 (1.03–1.25)
Missing 186
Mold at home No 7326 (95) 1.0 1.0
Yes 386 (5) 1.26 (0.69–2.32) 0.99 (0.81–1.20)
Missing 186
Problems to pay bills Never or seldom 7361 (96) 1.0 1.0
Yes, >6 months/year 348 (5) 0.84 (0.40–1.80) 0.92 (0.75–1.14)
Missing 189
Swedish parents Yes, both Swedish 297 (4) 1 1.0
One foreign 1792 (23) 1.03 (0.68–1.55) 0.93 (0.83–1.04)




>12 years 297 (4) 1.0 1.0
10–12 years 1792 (23) 1.14 (0.48–2.68) 1.13 (0.89–1.44)
≤9 years 5612 (73) 1.22 (0.54–2.76) 1.16 (0.92–1.47)
Missing
Type of housing Owned house 2384 (36) 1.0 1.0
Tenant-owned apartment 2242 (29) 0.69 (0.47–1.01) 0.93 (0.84–1.03)
Rented apartment 2616 (34) 0.84 (0.60–1.18) 0.86 (0.78–0.95)
Other 101 (1) — 1.14 (0.80–1.61)
Missing 156
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For the main cohort (n = 7898), we separately estimated
effects for Malmö vs. the remaining study area, to see if
results were consistent across geographical regions. We
also performed analyses restricted to children with high
socio-economic status (n = 3464), here defined as children
whose parents fulfilled all the following criteria; never
problems to pay bills, at least one parent with >12 years
education, and both parents born in Sweden. The ques-
tion about ability to pay bills was here not dichotomized
as in the main analysis, but instead a finer original classi-
fication was used, where “never problems to pay bills” was
separated from “seldom problems to pay bills”.
Finally, as a robustness test, we performed an analysis
for a model including all possibly relevant covariates, to
see if the results would differ from the stepwise model
and the unadjusted model. We also display model fit
measured by Akaike’s Information Criteria (AIC), for the
fully adjusted, the stepwise, and the unadjusted model,
based on individuals with complete covariate informa-
tion data (n = 5736).




Population characteristics, and incidence of allergy medi-
cation in relation to these characteristics, are displayed in
Table 1. Oral antihistamines were dispensed in a higher
proportion of children breastfed less than 8 months, with
parental allergy, with furred pets at home, or for those liv-
ing in Svedala or born certain years (2006, 2008, 2009).
Nasal anti-allergics were dispensed in a higher proportion
of boys than girls and for children born certain years
(2006, 2008).
Missing data and Kaplan-Meier survival curves
The Kaplan-Meier survival curves (Figs. 2 and 3) showed
almost no incidence for nasal anti-allergic medication
before the age of 2 years, and then increasing dispense
until age 6. For oral antihistamines, the incidence of dis-
pense was more evenly spread from age 0 to 6.
Incidence of dispensed allergy medication in relation to
traffic
There was no association between living close to traffic
and incidence of dispensed nasal anti-allergic medication
or oral antihistamines [Table 2]. Similar results were
seen in relation to NOX for nasal anti-allergic medica-
tion [Table 2]. For oral antihistamines, living in areas
with high NOX-levels was statistically significantly asso-
ciated with a lower incidence of dispense of oral antihis-
tamines [Table 2].
Sensitivity analyses
An analysis of all children for which health outcome and
exposure data were available (n = 26 128), unadjusted for
any factors, showed that living close to a road with high
traffic, or in areas with high level of NOx, was not asso-
ciated with incidence of dispensed nasal allergic medi-
cine. However, it was statistically significantly associated
with a lower incidence of dispense of oral antihistamines
(Additional file 1: Table S1).
For the main cohort (children with covariate infor-
mation, n = 7898), we stratified our analyses separately
for Malmö vs. the remaining municipalities, and the re-
sults were largely consistent across areas (Additional file 1:
Table S2).
We also performed an analysis restricted to children
with high socio-economic status (n = 3464) and the results
Table 1 Description of the main cohort, n = 7898 (Continued)
Municipality Vellinge 449 (6) 1.0 1.0
Svedala 664 (8) 0.70 (0.35–1.42) 1.25 (1.01–1.53)
Trelleborg 611 (8) 0.65 (0.39–1.08) 0.81 (0.69–0.96)
Malmö 6134 (78) 0.65 (0.32–1.32) 1.01 (0.82–1.25)
Missing 40
Birth year 2005 1066 (14) 1.0 1.0
2006 2395 (30) 1.94 (1.18–3.19) 1.22 (1.07–1.39)
2007 1664 (21) 1.66 (0.90–3.04) 1.10 (0.95–1.28)
2008 2179 (28) 2.56 (1.34–4.90) 1.17 (1.01–1.35)
2009 594 (8) 2.44 (0.68–8.77) 1.48 (1.19–1.84)
Birth season Winter (Dec–Feb) 1957 (25) 1.0 1
Spring (March–May) 1946 (25) 1.12 (0.76–1.67) 1.02 (0.91–1.15)
Summer (June–Aug) 1835 (23) 0.47 (0.30–0.73) 0.85 (0.75–0.95)
Autumn (Sep–Nov) 2160 (27) 0.59 (0.40–0.88) 0.87 (0.78–0.98)
HR (95 % CI) for dispense of medication in relation to population characteristics, for people who may have moved during study time
aUnadjusted — Too few individuals, numerically unstable results
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for this subgroup were similar to the results for the main
cohort (Additional file 1: Table S3).
Finally, as a robustness test, we performed an ana-
lysis for a model including all possibly relevant covar-
iates (“fully adjusted model”) and the results were similar
to the results for the stepwise and unadjusted model
(Additional file 1: Table S4). The model fit, measured by
AIC, was consistently better for the stepwise model for
oral antihistamines, and largely better for the stepwise
mode for nasal antiallergics, compared to the full and the
unadjusted models.
Discussion
There was no increased risk of ever dispense of prescribed
allergy medication among children 0–6 years, growing up
close to a road with high traffic intensity, or with high
levels of outdoor NOX at residence.
Strengths and limitations
A strength of the study was the large register-based health
outcome data which prevents recall and awareness bias,
although other types of biases may exist due to different
health-seeking behavior [11]. A strength was that most of
Fig. 2 Kaplan-Meier survival curves of nasal anti-allergic medication, by traffic intensity
Fig. 3 Kaplan-Meier survival curves of oral antihistamines, by traffic intensity
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these biases can however be reduced since we had con-
founder information which was used to stratify e.g., on
socio-economic status. A limitation was the low power for
nasal anti-allergic medication, which was inevitable since
this is a rare health outcome in young age. However, that
the results for the larger study population, which had
more power, were the same as for the cohort with ques-
tionnaire information strengthens that there is no higher
incidence of allergy in areas with high traffic pollution.
A major strength was also the exposure data in this
study. Residential addresses for each year since birth
were known, which exclude a migration bias which
could otherwise be expected to dilute the effects. We
also had validated high quality exposure data for NOX,
modeled with a high resolution, which further minimize
the risk of other exposure misclassification biases which
could be expected to dilute the effects. The exposure
situation in the area has been described in more detail in a
previous article. Mean NOX at birth year was 17 μg/m
3,
and the percentile distribution was 9.2, 11.8, 17.6, 21.1,
and 24.6 μg/m3 (10th, 25th, 50th, 75th, and 90th percent-
ile). Min, Max = (6.1, 45.9) μg/m3 [7].
A limitation was that prescribed dispensed medication
does not cover all allergy medication use, since some are
bought over the counter without prescription. Children
with dispense of prescribed allergy medication may be a
highly selected subgroup [11], and the results for this
group may not be generalizable to all children with al-
lergy. However, we believe that many parents are likely
to go to a doctor when their preschool children have
allergic problems, and that a large proportion of young
allergic children get allergy prescription compared to if
allergy develops in older age when over-the-counter
medication may make up a larger proportion. The valid-
ity of dispensed allergy medication as a proxy for allergy
incidence might thus decrease with age, since it is likely
that adults buy over-the-counter medication for e.g., aller-
gic rhinitis without seeing a doctor, and dispensed medi-
cation may then represent a small selection with more
severe disease. We believe this may become an increasing
problem if the cohort is followed after early childhood. A
doctor prescription is however likely to be more specific
for allergic symptoms than over-the-counter medication,
in all age groups, since clinical examination/anamnesis
excludes infectious rhinitis as a cause.
It should be noted that the overall prescription of
nasal corticosteroids in Scania has been increasing dur-
ing 2006–2011 [19], something which may explain that
children born in 2008–2009 had a higher incidence of
nasal anti-allergics than children born earlier in this
study. However, this did not affect our results since we
adjusted for year of birth. Finally, it should be noted that
nasal corticosteroids are not exclusively prescribed for
allergic disease, but can also be prescribed e.g. for nasal
polyposis.
Comparison with other epidemiological studies
Overall, epidemiological studies have shown conflicting
results of the relation between traffic and allergy. In a
review 2009 of the relation between air pollution and
sensitization in four birth cohorts, three of the birth
cohorts found some association with sensitization, while
one did not [4]. However, there was heterogeneity both in
what health outcome was associated with air pollution
and also in the exposure assessment. In some of the indi-
vidual studies associations have been found with inhalant
exposure such as pollen [20, 21]. In other studies how-
ever, associations were mainly found with food allergens
[22, 23]. In a meta-analysis by Gruzieva et al. [3], a stan-
dardized modelling technique was applied to all the four
cohorts, and also a fifth cohort, and this meta-analysis
found no overall association between air pollution and
allergic sensitization. In a recent meta-analysis by
Bowatte et al. [2], of birth cohort studies, they found
Table 2 Adjusted HR (95 % CI) for allergy medication, in
relation to traffic-related exposure, n = 7898
Allergy medicationa
Nasal anti-allergics Oral antihistamine
1st purchase 1st purchase
Heaviest road ≤100 m, birth addressb
0–8639 cars/day 1.0 1.0
≥ 8640 0.89 (0.61–1.29) 0.91 (0.83–1.00)
Heaviest road ≤100 m, never movedb
0–8639 cars/day 1.0 1.0
≥ 8640 0.83 (0.51–1.36) 0.90 (0.79–1.03)
NOX, birth address
c
≤ 15 μg/m3 1.0 1.0
15–25 0.84 (0.58–1.21) 0.86 (0.77–0.95)
> 25 0.86 (0.50–1.49) 0.81 (0.68–0.96)
NOX, never moved
c
≤ 15 μg/m3 1.0 1.0
15–25 0.95 (0.62–1.47) 0.88 (0.78–0.99)
> 25 0.95 (0.42–2.16) 0.77 (0.62–0.96)
NOX, lifetime mean
d
≤ 15 μg/m3 1.0 1.0
15–25 0.92 (0.62–1.35) 0.84 (0.75–0.93)
> 25 0.59 (0.23–1.50) 0.70 (0.56–0.89)
aAdjusted for sex, season, parental origin, year of birth, breastfeeding, and
parental allergy
bn = 6093 children had complete covariate information and traffic
exposure assessments
cn = 6091 children had complete covariate information and modeled
NOx concentrations
dThe number of children with complete covariate information and modeled
mean NOx during time at risk, was n = 5264 for nasal antiallergics, and n = 5317
for oral antihistamines
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that increasing exposure to PM 2.5 was associated
with sensitization to both aero- and food allergens.
There was also some evidence that traffic related air
pollution was associated with hay fever [24].
Few have investigated the relation with allergic rhinitis
in childhood, but there has been positive association in
some cohorts and cross-sectional studies [20, 25–30],
while some studies have found no association [31–36].
No other study has used medication data as a proxy for
allergy in long-term studies of traffic, although medica-
tion data has been associated with short-term effects of
pollen [37, 38] and to measure the relation to other risk
factors [8].
We have in a previous cross-sectional study found
an association with allergic but not non-allergic
asthma and rhinitis in adults [16]. We however found
no association with asthma medication in childhood
in the present cohort [7]. We have therefore hypothe-
sized that there may only be an association between
long-term exposure to air pollution and asthma after
early childhood.
Experimental evidence for an association between traffic
and allergy
For respiratory outdoor allergens such as birch pollen,
it has been suggested that nitration by Nitrogen Di-
oxide (NO2) and Ozone (O3) increases allergenicity
[39–42]. Antibodies to pollen may cross-react with
food allergens, but there is also support that diesel
exhaust particles could block oral tolerance mecha-
nisms and thereby contribute to food allergen sensitization
per se [43].
A general theory with experimental support is that air
pollution shifts Th1/Th2 response in the immune system,
thereby promoting allergy development of the Ig-E-
mediated type [44]. Particles can both act as immunomod-
ulators but also as vectors for respiratory exposure, and
also facilitate uptake by antigen-presenting-cells [45, 46].
In summary, there is ample evidence from experi-
mental studies that do support a relation between air
pollution and allergy, in a number of different pos-
sible ways [1, 47–50]. However, it is also very clear
that the development of allergy and sensitization is
not simple, and the mechanisms for allergy develop-
ment are mainly unknown. This can be illustrated by
the simple fact that it has still not been established if
growing up in a household with furred animals is a risk
factor, or a protecting factor, for allergy [51]. No clear
dose-relation between allergy development and allergen
exposure has been found [52].
Implications for further studies
Our study adds to the many studies which do not sup-
port a clear relation between traffic exposure and allergy
development in early childhood. However, some studies
find an association. It is obvious that this relationship in
case it exists, is not a simple one, and may be overridden
by other risk factors.
A complicating factor is that manifest allergy is a com-
bination of genetic factors, allergy-promoting and allergy-
protecting factors, and also actual exposure to allergen.
The result in this study weakly suggests that people living
in areas with high levels of NOX may even develop allergy
to a lesser degree then people living in unpolluted
areas. It is unlikely that traffic is a protecting factor,
but more likely that actual exposure to allergen or other
allergen-promoting factors differ. One factor that may dif-
fer between urban and rural areas are pollen counts, it has
been shown in one study that rural areas had pollen with
higher allergenicity, but a lower total level of pollen [53].
Further studies may try to get more data on local varia-
tions in pollen counts or birch-intensity in different areas.
Further studies of this child cohort in older age should
also try to complement with other allergy information
data, since it is uncertain how good dispensed allergy
medication is as a proxy since it can be bought over the
counter. Using complementary measures of allergy would
also be useful for result comparison, since few countries
have national medication registry data, which limits the
number of countries which can reproduce the present
study design.
Conclusions
There was no increased risk of ever dispense of pre-
scribed allergy medication among children 0–6 years,
growing up close to a road with high traffic intensity,
or high levels of NOX. These results may indicate
that traffic-related exposure is not a risk factor for
early onset allergy in children in southern Sweden.
However, children with dispense of prescribed allergy
medication may be a selected subgroup, and the re-
sults for this group may not be generalizable to all
children with allergy.
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